Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity <i>in Vivo</i>
Manuel Tsiang(Gilead Sciences (United States)), Craig S. Gibbs(Gilead Sciences (United States)), D. W. Lee(Gilead Sciences (United States)), Lisa R. Paborsky(Gilead Sciences (United States)), Cheri T. Mao(Gilead Sciences (United States)), Aakanksha Jain(Boston Children's Hospital), Kyla Dunn(Gilead Sciences (United States)), W.-X. Li(Gilead Sciences (United States)), Lawrence Leung(Stanford University), Steven Coutré(Georgetown University), Mark D. Matteucci(University of Auckland), S. Y. Matsumura(Gilead Sciences (United States))
Cited by 75
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825